{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:02:55Z","timestamp":1736139775951,"version":"3.32.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clml.2024.07.015","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T18:10:24Z","timestamp":1722449424000},"page":"e62-e69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimated Financial Savings From Clinical Studies at Oslo Myeloma Center in the Period 2015-2021"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7863-6533","authenticated-orcid":false,"given":"Lars Henrik Dahl","family":"Hamnvik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Eide-Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3914-5045","authenticated-orcid":false,"given":"Arne","family":"Fosseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik Hellem","family":"Schjesvold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.07.015_bib0001","unstructured":"Helse-og-Omsorgsdepartementet. Nasjonal handlingsplan for kliniske studier 2021-2025. 2021 11.01.2021; Available from: https:\/\/www.regjeringen.no\/no\/dokumenter\/nasjonal-handlingsplan-for-kliniske-studier\/id2880741\/."},{"key":"10.1016\/j.clml.2024.07.015_bib0002","unstructured":"Skogli, E. and M.G. Theie. Verdien av kliniske studier i Norge. 2017; Available from: https:\/\/www.menon.no\/publication\/verdien-kliniske-studier-norge\/."},{"key":"10.1016\/j.clml.2024.07.015_bib0003","unstructured":"O'Donnell, P. Playing catch-up with europe's decline in attracting clinical trials. 2023; Available from: https:\/\/www.appliedclinicaltrialsonline.com\/view\/playing-catch-up-with-europe-s-decline-in-attracting-clinical-trials."},{"key":"10.1016\/j.clml.2024.07.015_bib0004","unstructured":"Jaber, N. FDA approves BCMA-Targeted CAR T-cell therapy for multiple myeloma. 2021; Available from: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2021\/fda-ide-cel-car-t-multiple-myeloma."},{"journal-title":"Commer clin trls UK: Lord O'Shaughnessy rev - fnl rpt","article-title":"Department-for-science-innovation-and-technology and Department-of-health-and-social-care","year":"2023","key":"10.1016\/j.clml.2024.07.015_bib0005"},{"key":"10.1016\/j.clml.2024.07.015_bib0006","unstructured":"Sautter, A. and S. Aschenbrenner. Current developments in the field of clinical drug trials in Germany - adjusting parameters to shorten procedures before the start of a clinical trial. 2023; Available from: https:\/\/www.taylorwessing.com\/en\/insights-and-events\/insights\/2023\/09\/aktuelle-entwicklungen-im-bereich-klinischer-arzneimittelstudien."},{"key":"10.1016\/j.clml.2024.07.015_bib0007","unstructured":"World-Health-Organization. Number of clinical trials by year, country, WHO region and income group (1999-2022). 2023; Available from: https:\/\/www.who.int\/observatories\/global-observatory-on-health-research-and-development\/monitoring\/number-of-clinical-trials-by-year-country-who-region-and-income-group."},{"issue":"11","key":"10.1016\/j.clml.2024.07.015_bib0008","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:38:59Z","timestamp":1736059139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2152265024002842"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimated Financial Savings From Clinical Studies at Oslo Myeloma Center in the Period 2015-2021","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}